Participating in a clinical trial is a valuable health care option available to many patients at The Nebraska Medical Center. Participants are able to take a more active role in their own health care, gain access to new drugs and treatments before they become widely available, and help other patients by contributing to medical research.
The Nebraska Medical Center participates in a variety of clinical trials to test new, investigational drugs and to study new ways of using known treatments. By researching the latest and most innovative procedures and therapies, we can provide patients access to the newest treatments. The collaboration between researchers and health care providers in our transplant center allows for greater discovery and application of new knowledge.
Once a patient has been evaluated and approved for a transplant, they may be eligible for participation in a clinical trial. Patients deemed eligible to participate in a clinical trial have the opportunity to review the study protocol to determine what is expected. The protocol will list details including the schedule of tests, procedures, medications, dosages, schedule of doctor appointments and the duration of the study.
Choosing to enroll in a research study is a personal decision. It requires careful consideration of the potential advantages and disadvantages. If a patient decides to participate in the study, they will be asked to sign an informed consent document. This document is not a contract, and the patient may withdraw at any time. The information on this page describes investigational programs the intestinal transplant program currently participates in to help advance transplantation success.
Please contact our Clinical Studies Program Coordinator regarding any questions or for further information regarding the available research studies:
Kris Seipel
402-559-6022
kseipel@unmc.edu
More information on any sponsored study is also available at www.clinicaltrials.gov
Intestinal Protocols:
Studies of Inflammation, Immune Function and Infection in Intestinal Failure Patients
Principal Investigator:
David Mercer, MD, PhD
Description:
This study is seeking to identify a way to differentiate infection and rejection in an intestinal graft without having to biopsy the tissue.
Omegaven - Prospective Evaluation of Prenteral Omega-3 Fatty Acid Preparation (Omegaven) in Therapy of Patients with TPN-Induced Cholestasis
Principal Investigator:
David Mercer, MD, PhD
Please contact our Clinical Studies Program Coordinator regarding any questions or for further information regarding the available research studies:
Kris Seipel
402-559-6022
kseipel@unmc.edu
More information on any sponsored study is also available at www.clinicaltrials.gov
Transplant Center
